Give now!

Animal Health Research Center

Frederick D. Quinn

Frederick D. Quinn

Professor, Department Head
Athletic Association Professor of Infectious Diseases
Email: .(JavaScript must be enabled to view this email address)

About Frederick D. Quinn

Last year there were an estimated 10 million new cases of tuberculosis (TB) in humans worldwide and an estimated 1.6 million deaths. The primary agent is Mycobacterium tuberculosis. The number of TB animal deaths each year is unknown but likely higher. The primary animal TB agent is M. bovis. Importantly, the number of zoonotic TB cases (humans infected with M. bovis and animals with M. tuberculosis) is not known but likely under-reported since speciation of positive cases is not routinely performed outside the United States. The BCG vaccine is ineffective in human adults and is not widely used in animals. Human treatment involves a minimum of six months of combination antimicrobial therapy. Animal treatment is not feasible, and infected animals are typically euthanized. Johne's disease is a contagious, chronic, and usually fatal infection that affects primarily the small intestine of ruminants worldwide. Johne's disease is caused by Mycobacterium avium subspecies paratuberculosis. There is no effective vaccine or treatment for this disease.


The mission of this laboratory is to identify, isolate and analyze virulence factors from M. tuberculosisM. bovis, and M. paratuberculosis. The primary areas of research focus include: 1) developing novel animal and in vitro tissue models to help understand disease transmission, pathogenesis, and virulence differences among the various species and strains; 2) using animal models with microbiological, pathological, immunological and biomarker profiling to assess novel vaccine and diagnostic tests for TB and Johne’s disease; because the BCG vaccine is not effective in a large fraction of the population, we are currently attempting to assess a number of novel vaccine candidates; and 3) examine a number of mycobacterial genes in order define virulence regulation and control mechanisms of the host-pathogen interaction.

Educational Background

  • ​MS (1982) Indiana University
  • PhD (1982) Indiana University

Research Interests

  • Identification and analysis of virulence factors from Mycobacterium tuberculosis and other mycobacteria​

Selected Publications

Search PubMed for “quinn fd”

  • Marais, B.J., B.M. Buddle, L-M. de Klerk-Lorist, P. Nguipdop-Djomo, F. Quinn, and C. Greenblatt. BCG vaccination for bovine tuberculosis; conclusions from the Jerusalem One Health Workshop. Transbound Emerging Dis. 66(2):1037-1043.
  • Gupta, T, M. LaGatta, S. Helms, R.L. Pavlicek, S.O. Owino, K. Sakamoto, T. Nagy, S.B. Harvey, M. Papania, S. Ledden, K.T. Schultz, C. McCombs, F.D. Quinn, and RK Karls. 2018. Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs. Tuberculosis
  • Abreu R, L. Essler, A. Loy, F. Quinn, and P. Giri. Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages. Sci Rep. 2018 May 8;8(1):7296. PMID: 29740038
  • Castro-Garza, J., P. Garcia-Jacobo, L.G. Rivera-Morales, F. Quinn, J. Barber, R. Karls, D. Haas, S. Helms, H. Blumberg, J. Tapia, I. Luna-Cruz, A. Rendon, J. Vargas-Villarreal, L. Vera-Cabrera, C. Rodriguez-Padilla. 2017. Detection of anti-HspX antibodies and HspX protein in patient sera for the identification of recent latent infection byMycobacterium tuberculosis. PLoS One. 2017 Aug 16;12(8):e0181714. doi: 10.1371/journal.pone.0181714. eCollection 2017. PMID: 28813434.
  • Chen, Z., T. Gupta, P. Xu, S. Phan, A. Pickar, W. Yau, R.K. Karls, F.D. Quinn, K. Sakamoto, and B. He. 2015. Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice. Vaccine. 33:7217-7224.
  • Chen, X., K. Sakamoto, F.D. Quinn, C. Huanchun, and Z.F. Fu. 2015. Lack of intracellular replication of M. tuberculosis and M. bovis BCG caused by delivering bacilli to lysosomes in murine brain microvascular endothelial cells. Oncotarget. 6:32456-32467.

Be part of the CVM Team. Give today!